Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 4Unknown 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 12Endometrial Neoplasms 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Neoplasms 3Uterine Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Prostatic Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Melanoma 1Laryngeal Neoplasms 1Kenny-Caffey syndrome, Type 1 1Hyperglycemia 1High Grade Serous Ovarian Cancer 1Head and Neck Neoplasms 1Genital Neoplasms, Female 1Genital Diseases, Female 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Recurrence × olaparib × Clear all
NCT04015739 2022-08-17

BOLD

ARCAGY/ GINECO GROUP

Phase 2 Unknown
74 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Recurrence

NCT01650376 2018-03-23

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Swedish Medical Center

Phase 1/2 Unknown
52 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡